Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institute of Oncology Ljubljana
Prostate cancer is one of the most common malignancies in men. Individuals carrying germline mutations in BRCA1 and BRCA2 genes are at increased risk of developing prostate cancer and may benefit from targeted screening strategies. The IMPACT study was designed to evaluate early detection approaches in men with hereditary predisposition to prostate cancer.
This study represents a follow-up assessment within the IMPACT framework. Men with BRCA1 or BRCA2 mutations and a control group of non-carriers are contacted by telephone to collect updated information on prostate cancer diagnosis and other relevant changes in personal and family medical history during the year 2025.
The collected information will contribute to evaluation of prostate cancer incidence in genetically predisposed individuals and may support the development and optimization of targeted prostate cancer screening programs for high-risk populations.
Age
18–any
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Male participants aged 18 years or older
BRCA1 or BRCA2 mutation carriers or non-carrier controls enrolled in the IMPACT study
Eligible for targeted prostate cancer screening and follow-up
Ability to participate in telephone follow-up interview
Written informed consent provided
You may not be if
History of prostate cancer prior to enrollment
Inability to provide informed consent or complete follow-up procedures
Any condition that, in the investigator's opinion, would interfere with study participation or data quality
